Biology of Blood and Marrow Transplantation
Volume 9, Issue 1 , Pages 4-37 , January 2003

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review

  • Theresa Hahn

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • John R. Wingard

      Affiliations

    • University of Florida College of Medicine, Gainesville, Florida
    • ,
  • Kenneth C. Anderson

      Affiliations

    • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    • ,
  • William I. Bensinger

      Affiliations

    • The Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • James R. Berenson

      Affiliations

    • Cedars Sinai Medical Center, Los Angeles, California
    • ,
  • Greg Brozeit

      Affiliations

    • International Myeloma Foundation, North Hollywood, California
    • ,
  • Joseph R. Carver

      Affiliations

    • Abramson Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Robert A. Kyle

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • Philip L. McCarthy Jr

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York

Received 18 October 2002 ,Accepted 22 October 2002.

References 

  1. Hahn T, Wolff SN, Czuczman M, et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence based review. Biol Blood Marrow Transplant. 2001;7:308–331
  2. Jones R, Horowitz M, Wall D, et al.  Policy statement regarding the methodology of evidence-based reviews in evaluating the role of blood and marrow transplantation in the therapy of selected diseases. Biol Blood Marrow Transplant. 2000;6:524–525
  3. Attal M, Harousseau JL, Stoppa AM, et al.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  4. Barlogie B, Jagannath S, Vesole DH, et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  5. Lenhoff S, Hjorth M, Holmberg E, et al.  Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000;95:7–11
  6. Palumbo A, Triolo S, Argentino C, et al.  Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248–1253
  7. Alexanian R, Weber D, Giralt S, et al.  Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001;27:1037–1043
  8. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278–4282
  9. Gianni AM, Tarella C, Bregni M, et al.  High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J Clin Oncol. 1994;12:503–509
  10. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood. 1994;83:512–516
  11. Malpas JS, Ganjoo RK, Johnson PWM, et al.  Myeloma during a decade: clinical experience in a single centre. Ann Oncol. 1995;6:11–18
  12. Gertz MA, Lacy MQ, Inwards DJ, et al.  Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999;23:221–226
  13. Fermand JP, Ravaud P, Chevret S, et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131–3136
  14. Harousseau JL, Milpied N, Laporte JP, et al.  Double-intensive therapy in high-risk multiple myeloma. Blood. 1992;79:2827–2833
  15. Hawkins T, Horvath N, Rawling C, et al.  An incremental response to high-dose therapy in multiple myeloma. Bone Marrow Transplant. 1996;17:929–935
  16. Alegre A, Díaz-Mediavilla J, San-Miguel J, et al.  Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Español de Trasplante Hematopoyético-GETH) and PETHEMA. Bone Marrow Transplant. 1998;21:133–140
  17. Lokhorst HM, Sonneveld P, Cornelissen JJ, et al.  Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant. 1999;23:317–322
  18. Seiden MV, Schlossman R, Andersen J, et al.  Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995;17:87–93
  19. Anderson KC, Andersen J, Soiffer R, et al.  Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993;82:2568–2576
  20. Anderson KC, Barut BA, Ritz J, et al.  Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991;77:712–720
  21. Björkstrand B, Ljungman P, Svensson H, et al.  Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711–4718
  22. Varterasian M, Janakiraman N, Karanes C, et al.  Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol. 1997;20:462–466
  23. Reynolds C, Ratanatharathorn V, Adams P, et al.  Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2001;27:801–807
  24. Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant. 1997;19:783–789
  25. Gore ME, Viner C, Meldrum M, et al.  Intensive treatment of multiple myeloma and criteria for complete remission. Lancet. 1989;2:879–882
  26. Attal M, Huguet F, Schlaifer D, et al.  Intensive combined therapy for previously untreated aggressive myeloma. Blood. 1992;79:1130–1136
  27. Cunningham D, Paz-Ares L, Milan S, et al.  High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12:759–763
  28. Hovenga S, de Wolf JT, Guikema JEJ, et al.  Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant. 2000;25:723–728
  29. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301
  30. Barlogie B, Alexanian R, Dicke K, et al.  High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–872
  31. Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol. 1994;87:730–734
  32. Gertz MA, Pineda AA, Chen MG, et al.  Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci. 1995;309:152–161
  33. Rajkumar SV, Fonseca R, Lacy MQ, et al.  Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999;23:1267–1272
  34. Vesole DH, Crowley JJ, Catchatourian R, et al.  High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol. 1999;17:2173–2179
  35. Mansi JL, Cunningham D, Viner C, et al.  Repeat administration of high-dose melphalan in relapsed myeloma. Br J Cancer. 1993;68:983–987
  36. Fermand JP, Levy Y, Gerota J, et al.  Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 1989;73:20–23
  37. Fermand JP, Chevret S, Ravaud P, et al.  High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood. 1993;82:2005–2009
  38. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80:1666–1672
  39. Marit G, Fabares C, Pico JL, et al.  Autologous peripheral-blood progenitor-cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma. J Clin Oncol. 1996;14:1306–1313
  40. Williams CD, McSweeney EN, Mills W, et al.  Autologous bone marrow transplantation in multiple myeloma: a single centre experience of 23 patients. Leuk Lymphoma. 1994;15:273–279
  41. Mahendra P, Hood IM, Johnson D, et al.  Autografting for multiple myeloma: a 5-year experience at a single institution. Bone Marrow Transplant. 1995;16:759–763
  42. Sirohi B, Powles R, Treleaven J, et al.  The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000;25:533–539
  43. Badros A, Barlogie B, Siegel E, et al.  Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600–607
  44. Aslan T, Fassas AB-T, Desikan R, et al.  Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant. 1999;24:505–509
  45. Badros A, Barlogie B, Siegel E, et al.  Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–829
  46. Ballester OF, Tummala R, Janssen WE, et al.  High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997;20:653–656
  47. Tosi P, Zamagni E, Ronconi S, et al.  Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia. 2000;14:1310–1313
  48. Tricot G, Alberts DS, Johnson C, et al.  Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–952
  49. Raje N, Powles R, Horton C, et al.  Comparison of marrow versus blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer. 1997;75:1684–1689
  50. Harousseau JL, Attal M, Divine M, et al.  Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant. 1995;15:963–969
  51. Stewart AK, Vescio R, Schiller G, et al.  Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001;19:3771–3779
  52. Vescio R, Schiller G, Stewart AK, et al.  Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93:1858–1868
  53. Abonour R, Scott KM, Kunkel LA, et al.  Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:957–963
  54. Lemoli RM, Fortuna A, Motta MR, et al.  Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood. 1996;87:1625–1634
  55. Lemoli RM, Fortuna A, Raspadori D, et al.  Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma. Leuk Lymphoma. 1997;26:1–11
  56. Lemoli RM, Cavo M, Fortuna A. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother. 1996;5:339–349
  57. Schiller G, Vescio R, Freytes C, et al.  Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant. 1998;21:141–145
  58. Schiller G, Vescio R, Freytes C, et al.  Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood. 1995;86:390–397
  59. Dyson PG, Horvath N, Joshua D, et al.  CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma. Bone Marrow Transplant. 2000;25:1175–1184
  60. Patriarca F, Damiani D, Fanin R, et al.  High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Haematologica. 2000;85:269–274
  61. Gupta D, Bybee A, Cooke F, et al.  CD34+−selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol. 1999;104:166–177
  62. Michallet M, Philip T, Philip I, et al.  Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol. 2000;28:858–870
  63. Lemoli RM, Martinelli G, Zamagni E, et al.  Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000;95:2234–2239
  64. Gandhi MK, Jestice HK, Scott MA, et al.  A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Bone Marrow Transplant. 1999;24:369–375
  65. Reece DE, Barnett MJ, Connors JM, et al.  Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant. 1993;11:139–146
  66. Lemoli RM, Martinelli G, Olivieri A, et al.  Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. Br J Haematol. 1999;107:419–428
  67. Rasmussen T, Björkstrand B, Andersen H, et al.  Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study. Exp Hematol. 2002;30:82–88
  68. Barbui A, Galli M, Dotti G, et al.  Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol. 2002;116:202–210
  69. Barlogie B, Jagannath S, Desikan KR, et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  70. Vesole DH, Barlogie B, Jagannath S, et al.  High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84:950–956
  71. Siegel DS, Desikan KR, Mehta J, et al.  Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54
  72. Björkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplant. 1995;15:367–371
  73. Moreau P, Facon T, Attal M, et al.  Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9505 randomized trial. Blood. 2002;99:731–735
  74. Tribalto M, Amadori S, Cudillo L, et al.  Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica. 2000;85:52–58
  75. Tribalto M, Papa G, Coppetelli U, et al.  Treatment of multiple myeloma with autologous blood stem cell transplantation. Preliminary results of an Italian multicentric pilot study. Int J Artif Organs. 1993;16:51–56
  76. Meloni G, Capria S, Trasarti S, et al.  High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study. Bone Marrow Transplant. 2000;26:1045–1049
  77. Mansi J, da Costa F, Viner C, et al.  High-dose busulfan in patients with myeloma. J Clin Oncol. 1992;10:1569–1573
  78. Long GD, Chao NJ, Hu WW, et al.  High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. Cancer. 1996;78:2502–2509
  79. Dimopoulos MA, Alexanian R, Przepiorka D, et al.  Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993;82:2324–2328
  80. Shimoni A, Smith TL, Aleman A, et al.  Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant. 2001;27:821–828
  81. Dimopoulos MA, Weber DM, Hester J, et al.  Intensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1994;13:479–484
  82. Alegre A, Lamana M, Arranz R, et al.  Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol. 1995;91:380–386
  83. Ventura GJ, Barlogie B, Hester JP, et al.  High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplant. 1990;5:265–268
  84. Barlogie B, Jagannath S, Naucke S, et al.  Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant. 1998;21:1101–1107
  85. Bensinger WI, Rowley SD, Demirer T, et al.  High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol. 1996;14:1447–1456
  86. Goldschmidt H, Hegenbart U, Wallmeier M, et al.  High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol. 1997;8:243–246
  87. Goldschmidt H, Hegenbart U, Wallmeier M, et al.  Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Cancer Res. 1998;144:27–35
  88. Chen CI, Abraham R, Tsang R, et al.  Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant. 2001;27:177–182
  89. Lahuerta JJ, Grande C, Blade J, et al.  Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymphoma. 2002;43:67–74
  90. Lahuerta JJ, Martinez-Lopez J, Grande C, et al.  Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol. 2000;109:138–147
  91. Desikan KR, Tricot G, Dhodapkar M, et al.  Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant. 2000;25:483–487
  92. Palumbo A, Triolo S, Baldini L, et al.  Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Haematologica. 2000;85:508–513
  93. Palumbo A, Pileri A, Triolo S, et al.  Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant. 1997;19:23–29
  94. Rajkumar SV, Fonseca R, Lacy MQ, et al.  Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999;17:1551–1557
  95. Rajkumar SV, Fonseca R, Macy MQ, et al.  Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999;23:1261–1266
  96. Jagannath S, Barlogie B, Dicke K, et al.  Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood. 1990;76:1860–1866
  97. Majolino I, Vignetti M, Meloni G, et al.  Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica. 1999;84:844–852
  98. Sirohi B, Powles R, Kulkarni S, et al.  Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001;28:29–37
  99. Sirohi B, Powles R, Kulkarni S, et al.  Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer. 2001;85:325–332
  100. Moreau P, Milpied N, Mahé B, et al.  Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant. 1999;23:1003–1006
  101. Björkstrand B, Goldstone AH, Ljungman P, et al.  Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma. 1994;15:265–272
  102. Dumontet C, Ketterer N, Espinouse D, et al.  Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant. 1998;21:1037–1041
  103. Gertz MA, Lacy MQ, Inwards DJ, et al.  Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant. 2000;26:45–50
  104. Porrata LF, Gertz MA, Inwards DJ, et al.  Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579–585
  105. Worel N, Greinix H, Ackermann J, et al.  Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol. 2001;80:345–348
  106. Rajkumar SV, Fonseca R, Lacy MQ, et al.  Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1999;24:497–503
  107. Boccadoro M, Omedé P, Dominietto A, et al.  Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant. 2000;25:25–29
  108. Desikan KR, Dhodapkar MV, Hough A, et al.  Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27:315–319
  109. Lecouvet FE, Dechambre S, Malghem J, et al.  Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging. Am J Roentgenol. 2001;176:91–96
  110. Desikan R, Barlogie B, Sawyer J, et al.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008–4010
  111. Tricot G, Sawyer JR, Jagannath S, et al.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659–2666
  112. Vesole DH, Tricot G, Jagannath S, et al.  Autotransplants in multiple myeloma: what have we learned?. Blood. 1996;88:838–847
  113. Tricot G, Spencer T, Sawyer J, et al.  Predicting long-term (≥5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002;116:211–217
  114. Gertz MA, Lacy MQ, Inwards DJ, et al.  Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1997;20:375–380
  115. Millar BC, Millar JL, Bell JBG, et al.  Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. Bone Marrow Transplant. 1996;18:871–878
  116. Tricot G, Jagannath S, Vesole D, et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–596
  117. Rajkumar SV, Fonseca R, Dewald GW, et al.  Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113:73–77
  118. Govindarajan R, Jagannath S, Flick JT, et al.  Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349–353
  119. Maia DM, Kell DL, Goates JJ, Warnke RA. The significance of light chain-restricted bone marrow plasma cells after peripheral blood stem cell transplantation for multiple myeloma. Am J Clin Pathol. 1997;107:643–652
  120. Lahuerta JJ, Martinez-Lopez J, de la Serna J, et al.  Remission status defined by immunofixation versus electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol. 2000;109:438–446
  121. Gahrton G, Svensson H, Björkstrand B, et al.  Syngeneic transplantation in multiple myeloma—a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999;24:741–745
  122. Bensinger WI, Demirer T, Buckner CD, et al.  Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant. 1996;18:527–531
  123. Gahrton G, Tura S, Ljungman P, et al.  Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325:1267–1273
  124. Gahrton G, Tura S, Belanger C, et al.  Allogeneic bone marrow transplantation in patients with multiple myeloma. Eur J Haematol. 1989;43:182–185
  125. Gahrton G, Tura S, Flesch M, et al.  Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry. Hematol Oncol. 1988;6:181–186
  126. Gahrton G, Tura S, Flesch M, et al.  Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation. Blood. 1987;69:1262–1264
  127. LeBlanc R, Montminy-Métivier S, Bélanger R, et al.  Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 2001;28:841–848
  128. Reece DE, Shepard JD, Klingemann H-G, et al.  Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:117–123
  129. Majolino I, Corradini P, Scimé R, et al.  Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:449–455
  130. Gahrton G, Svensson H, Cavo M, et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209–216
  131. Cavo M, Bandini G, Benni M, et al.  High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 1998;22:27–32
  132. Badros A, Barlogie B, Siegel E, et al.  Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002;20:1295–1303
  133. Gahrton G, Tura S, Ljungman P, et al.  Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312–1322
  134. Bensinger WI, Buckner CD, Anasetti C, et al.  Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787–2793
  135. Kulkarni S, Powles RL, Treleaven JG, et al.  Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant. 1999;23:675–680
  136. Badros A, Tricot G, Toor A, et al.  ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002;42:205–209
  137. Attal M, Huguet F, Schlaifer D, et al.  Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. Bone Marrow Transplant. 1991;8:125–128
  138. Cunningham D, Powles R, Malpas J, et al.  A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998;102:495–502
  139. Powles R, Raje N, Milan S, et al.  Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant. 1997;20:435–443
  140. Powles R, Raje N, Horton C, et al.  Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma. 1996;21:421–427
  141. Björkstrand B, Svensson H, Goldschmidt H, et al.  Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27:511–515
  142. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.  Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031–3037
  143. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206–4211
  144. Salama M, Nevill T, Marcellus D, et al.  Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000;26:1179–1184
  145. Alyea E, Weller E, Schlossman R, et al.  T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934–939
  146. Badros A, Barlogie B, Morris C, et al.  High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574–2579
  147. Tricot G, Jagannath S, Vesole DH, et al.  Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995;16:7–11
  148. Mehta J, Tricot G, Jagannath S, et al.  Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?. Bone Marrow Transplant. 1998;21:887–892
  149. Garban F, Attal M, Rossi IF, Paven C, Fegueux , Sotto JJ, et al. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia. 2001;15:642–646
  150. Singhal S, Mehta J, Desikan K, et al.  Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Bone Marrow Transplant. 1999;24:13–17
  151. Mehta J, Tricot G, Jagannath S, et al.  High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant. 1997;20:113–116
  152. Gulbrandsen N, Wisløff F, Nord E, Lenhoff S, Hjorth M, Westin J, et al. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support versus melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol. 2001;66:328–336
  153. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer. 1994;30A:457–459
  154. Henon P, Donatini B, Eisenmann JC, Becker M, Beck-Wirth G. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant. 1995;16:19–25
  155. Duncan N, Hewetson M, Powles R, Raje N, Mehta J. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1996;18:1175–1178
  156. Jagannath S, Vesole DH, Zhang M, et al.  Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20:445–450
  157. Buijt I, Ossenkoppele GJ, Uyl-de Groot CA, Huijgens PC. Costs of intensive treatment and follow-up of patients with multiple myeloma. Anticancer Drugs. 1998;9:889–897
  158. Trippoli S, Messori A, Becagli P, Alterini R, Tendi E. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation. Oncol Rep. 1998;5:1475–1482
  159. Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol. 2001;113:1015–1019
  160. López-Pérez R, García-Sanz R, González D, et al.  Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28:665–672
  161. López-Pérez R, García-Sanz R, González D, et al.  The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia. 2000;14:1493–1499
  162. Reiman T, Seeberger K, Taylor BJ, et al.  Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood. 2001;98:2791–2799
  163. Chiusolo P, Sica S, Piccirillo N, et al.  Molecular and clinical follow-up after stem cell transplantation for multiple myeloma. Ann Hematol. 2001;80:90–95
  164. Swedin A, Lenhoff S, Olofsson T, Thuresson B, Westin J. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. Br J Haematol. 1998;103:1145–1151
  165. Mariette X, Fermand J-P, Brouet J-C. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant. 1994;14:47–50
  166. Vescio RA, Han EJ, Schiller GJ, et al.  Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant. 1996;18:103–110
  167. Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley AA. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol. 1996;92:614–619
  168. Kiel K, Cremer FW, Ehrbrecht E, et al.  First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant. 1998;21:1109–1115
  169. Thunberg U, Bånghagen M, Bengtsson M, et al.  Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma. Br J Haematol. 1999;104:546–552
  170. Martinelli G, Terragna C, Lemoli RM, et al.  Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. Haematologica. 1999;84:397–404
  171. Davies FE, Forsyth PD, Rawstron AC, et al.  The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol. 2001;112:814–819
  172. Dreyfus F, Ribrag V, Leblond V, et al.  Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant. 1995;15:707–711
  173. Rasmussen T, Jensen L, Honoré L, Johnsen HE. Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma. Blood. 2000;96:4357–4359
  174. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92:2844–2855
  175. Martinelli G, Terragna C, Zamagni E, et al.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000;18:2273–2281
  176. Corradini P, Voena C, Tarella C, et al.  Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol. 1999;17:208–215
  177. Corradini P, Voena C, Astolfi M, et al.  High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood. 1995;85:1596–1602
  178. Cavo M, Terragna C, Martinelli G, et al.  Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood. 2000;96:355–357
  179. Willems P, Verhagen O, Segeren C, et al.  Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood. 2000;96:63–70
  180. Ladetto M, Donovan JW, Harig S, et al.  Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant. 2000;6:241–253
  181. Sezer O, Niemöller K, Kaufmann O, et al.  Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Haematol. 2001;66:238–244
  182. Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia. 1999;13:469–472
  183. Goasguen JE, Zandecki M, Mathiot C, et al.  Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res. 1999;23:1133–1140
  184. Witzig TE, Gertz MA, Pineda AA, Kyle RA, Greipp PR. Detection of monoclonal plasma cells in the peripheral blood stem cell harvests of patients with multiple myeloma. Br J Haematol. 1995;89:640–642
  185. Rajkumar SV, Fonseca R, Dispenzieri A, et al.  Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001;68:269–275
  186. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood. 2000;96:2697–2702
  187. San Miguel JF, Almeida J, Mateo G, et al.  Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002;99:1853–1856
  188. Nowak R, Oelschlägel U, Range U, et al.  Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy. Bone Marrow Transplant. 1999;23:895–900
  189. Pope B, Brown R, Gibson J, Joshua D. Plasma cells in peripheral blood stem cell harvests from patients with multiple myeloma are predominantly polyclonal. Bone Marrow Transplant. 1997;20:205–210
  190. Genevieve F, Zandecki M, Laï J-L, et al.  Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist?. Leukemia. 1999;13:641–644
  191. Dascalescu CM, Callanan M, Chauvet M, et al.  Interphase FISH: a rapid method for detecting malignant plasma cells in multiple myeloma patients submitted to autologous transplantation. Bone Marrow Transplant. 1999;23:687–694
  192. Kiel K, Cremer FW, Rottenburger C, et al.  Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;23:1019–1027
  193. Almeida J, Orfao A, Ocqueteau M, et al.  High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121–131
  194. Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al.  Combining an allogeneic graft-versus-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. [abstract] Blood. 2001;98:434a
  195. Attal M, Harousseau JL, Facon T, et al.  Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 94). [abstr] Blood. 2002;100:5a
  196. Segeren CM, Sonneveld P, Van der Holt B, et al.  Myeloablative treatment following intensified chemotherapy in untreated multiple myeloma: a prospective, randomized phase III study. [abstract] Blood. 2001;98:815a
  197. Blade J, Sureda A, Ribera AM, et al.  High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. [abstract] Blood. 2001;98:815a
  198. Kropff M, Schneider P, Heyll A, Haas R, Berdel WE. Randomized trial comparing an intensified therapy (HD-IMC) with a standard high-dose therapy (HD-M) for multiple myeloma. [abstract] Blood. 2000;96:797a

☆ Correspondence and reprint requests: Theresa Hahn, PhD, Roswell Park Cancer Institute, Department of Medicine, Elm & Carlton Sts, Buffalo, NY 14263 (e-mail: Theresa.Hahn@RoswellPark.org).

PII: S1083-8791(02)00005-8

doi: 10.1053/bbmt.2003.50002

Biology of Blood and Marrow Transplantation
Volume 9, Issue 1 , Pages 4-37 , January 2003

Article Tools

* Image Usage & Resolution